Related Experiment Video
Updated: May 9, 2026

Targeting Neuronal Fiber Tracts for Deep Brain Stimulation Therapy Using Interactive, Patient-Specific Models
Published on: August 12, 2018
Modeling and simulation as a tool to bridge efficacy and safety data in special populations
L Harnisch1, T Shepard, G Pons
1Pfizer, Pharmacometrics, Global Clinical Pharmacology, Sandwich, UK.
Abstract:
The registration and approval of novel medicines have traditionally been based on evidence arising from large prospective trials. Such an approach is often not possible or unsuitable to evaluate the benefit-risk balance in special populations (e.g., children, ethnic groups, rare diseases). Inferences by modeling and simulation can play a major role in evidence synthesis. A framework is proposed that promotes its acceptability and the basis for decision making during development, registration, and therapeutic use of drugs.CPT: Pharmacometrics & Systems Pharmacology (2013) 2, e28; doi:10.1038/psp.2013.6; advance online publication 27 February 2013.
Related Concept Videos
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Analysis of Population Pharmacokinetic Data
Modeling in Therapy
Participant Modeling
Participant modeling involves therapists demonstrating calm and effective behaviors in situations...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Mechanistic Models: Compartment Models in Individual and Population Analysis
Bioavailability Study Design: Healthy Subjects Versus Patients
